Dapsone adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{Dapsone}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DAPSONE TABLET [JACOBUS PHARMACEUTICAL COMPANY,...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Adverse Reactions== | |||
In addition to the warnings listed above, the following syndromes and serious reactions have been reported in patients on Dapsone. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DAPSONE TABLET [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0792169d-c6f9-4af0-93ae-b75d710c47a9 | publisher = | date = | accessdate = }}</ref> | ===Hematologic Effects=== | ||
Dose-related hemolysis is the most common adverse effect and is seen in patients with or without G6PD deficiency. Almost all patients demonstrate the inter-related changes of a loss of 1-2g of hemoglobin, an increase in the [[reticulocytes]] (2-12%), a shortened red cell life span and a rise in [[methemoglobin]]. G6PD deficient patients have greater responses. | |||
===Nervous System Effects=== | |||
[[Peripheral neuropathy]] is a definite but unusual complication of Dapsone therapy in non-leprosy patients. Motor loss is predominant. If muscle weakness appears, Dapsone should be withdrawn. Recovery on withdrawal is usually substantially complete. The mechanism of recovery is reported by axonal regeneration. Some recovered patients have tolerated retreatment at reduced dosage. In leprosy this complication may be difficult to distinguish from a leprosy reactional state. | |||
===Body As A Whole=== | |||
In addition to the warnings and adverse effects reported above, additional adverse reactions include: nausea, vomiting, abdominal pains, [[pancreatitis]], [[vertigo]], blurred vision, tinnitus, insomnia, fever, headache, psychosis, [[phototoxicity]], [[pulmonary eosinophilia]], tachycardia, [[albuminuria]], the [[nephrotic syndrome]], [[hypoalbuminemia]] without proteinuria, [[renal papillary necrosis]], male infertility, [[drug-induced Lupus]] erythematosus and an [[infectious mononucleosis-like syndrome]]. In general, with the exception of the complications of severe anoxia from overdosage (retinal and optic nerve damage, etc.) these adverse reactions have regressed off drug.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DAPSONE TABLET [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0792169d-c6f9-4af0-93ae-b75d710c47a9 | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 22:41, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
In addition to the warnings listed above, the following syndromes and serious reactions have been reported in patients on Dapsone.
Hematologic Effects
Dose-related hemolysis is the most common adverse effect and is seen in patients with or without G6PD deficiency. Almost all patients demonstrate the inter-related changes of a loss of 1-2g of hemoglobin, an increase in the reticulocytes (2-12%), a shortened red cell life span and a rise in methemoglobin. G6PD deficient patients have greater responses.
Nervous System Effects
Peripheral neuropathy is a definite but unusual complication of Dapsone therapy in non-leprosy patients. Motor loss is predominant. If muscle weakness appears, Dapsone should be withdrawn. Recovery on withdrawal is usually substantially complete. The mechanism of recovery is reported by axonal regeneration. Some recovered patients have tolerated retreatment at reduced dosage. In leprosy this complication may be difficult to distinguish from a leprosy reactional state.
Body As A Whole
In addition to the warnings and adverse effects reported above, additional adverse reactions include: nausea, vomiting, abdominal pains, pancreatitis, vertigo, blurred vision, tinnitus, insomnia, fever, headache, psychosis, phototoxicity, pulmonary eosinophilia, tachycardia, albuminuria, the nephrotic syndrome, hypoalbuminemia without proteinuria, renal papillary necrosis, male infertility, drug-induced Lupus erythematosus and an infectious mononucleosis-like syndrome. In general, with the exception of the complications of severe anoxia from overdosage (retinal and optic nerve damage, etc.) these adverse reactions have regressed off drug.[1]
References
Adapted from the FDA Package Insert.